(Q42849496)

8 November 2017

title

The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice (English)

1 reference

8 November 2017

1 reference

Daiju Fukuda

1

1 reference

8 November 2017

Soichiro Enomoto

2

1 reference

8 November 2017

Yoichiro Hirata

3

1 reference

8 November 2017

Ryozo Nagai

4

1 reference

8 November 2017

Masataka Sata

5

1 reference

8 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20970951

8 August 2024

publication date

1 December 2010

1 reference

full work available at URL

8 November 2017

https://api.elsevier.com/content/article/PII:S0753332210001642?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

https://api.elsevier.com/content/article/PII:S0753332210001642?httpAccept=text/plain

8 August 2024

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Biomedicine and Pharmacotherapy

8 August 2024

published in

1 reference

8 November 2017

volume

64

1 reference

8 November 2017

issue

10

1 reference

8 November 2017

page(s)

712-717

1 reference

Atherosclerosis — An Inflammatory Disease

8 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis

8 August 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice.

8 August 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Clinical trial update: focus on the ONTARGET study

8 August 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan

8 August 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin

8 August 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

8 August 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

8 August 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial

8 August 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors

8 August 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

8 August 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome

8 August 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

8 August 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

8 August 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome

8 August 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

8 August 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.

8 August 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Telmisartan: a review of its use in the management of hypertension

8 August 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

The Clinical Significance of PPAR Gamma Agonism

8 August 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Peroxisome proliferator-activated receptor-γ agonists in atherosclerosis: current evidence and future directions

8 August 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change

8 August 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Macrophages: an elusive yet emerging therapeutic target of atherosclerosis.

8 August 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice

8 August 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma

8 August 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

8 August 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Abdominal obesity and the spectrum of global cardiometabolic risks in US adults

8 August 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease

8 August 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Vascular angiotensin AT2 receptors in hypertension and ageing

8 August 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

8 August 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

PPARgamma in endothelial cells influences high fat diet-induced hypertension

8 August 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect

8 August 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.BIOPHA.2010.09.014

8 August 2024

Identifiers

1 reference

8 November 2017

1 reference